Categories Earnings, Health Care

Arrowhead Pharmaceuticals (ARWR): FY 2019 Earnings Snapshot

—  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported earnings of 69 cents per share during fiscal year 2019, compared to a loss of 65 cents per share a year ago.

— For the full year, revenue rose to $168.7 million,  vs. $16.1 million last year.

— During Q4, the company started dosing patients in an adaptive design Phase 2/3 trial, called SEQUOIA, with the potential to serve as a pivotal registrational study of ARO-AAT.

— ARWR shares have more-than-quadrupled since the beginning of this year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Also Read:  Bristol Myers looks to expand cardiovascular portfolio with MyoKardia acquisition

Most Popular

Infographic: Seagate Technology (STX) Q1 earnings drop but beat view

Seagate Technology plc (NASDAQ: STX), a leading provider of data storage solutions, Thursday said its earnings declined in the first quarter of 2021, owing to a 10% fall in revenues.

INTC Earnings: All you need to know about Intel Q3 2020 earnings results

Intel Corporation (NASDAQ: INTC) reported third quarter 2020 earnings results today. Revenue fell 4% year-over-year to $18.3 billion. GAAP net income decreased 29% to $4.3 billion while EPS dropped 25%

AT&T (T) Earnings: Key financials and quarterly highlights

AT&T Inc. (NYSE: T) today reported its third quarter financial results for the period ended September 30, 2020. Net income for the third quarter was $2.8 billion, or $0.39 per

Top